tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Berney T et al. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. 2004 Transplant. Proc. pmid:15194390
Gonzalez Molina M et al. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine. 2007 Transplant. Proc. pmid:17889126
Undre NA and Schäfer A Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. 1998 Transplant. Proc. pmid:9636512
Masutani K et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. 2014 Transplant. Proc. pmid:24655972
Gavela E et al. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715842
Cherala G et al. Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation. 2011 Transplant. Proc. pmid:22172831
Latorre A et al. Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. 2002 Transplant. Proc. pmid:11959186
Stringa P et al. Pretreatment Combination Reduces Remote Organ Damage Secondary to Intestinal Reperfusion Injury in Mice: Follow-up Study. Transplant. Proc. pmid:26915870
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Kim HC and Park SB Mycophenolate mofetil-induced ischemic colitis. 2000 Transplant. Proc. pmid:11119990
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Ringe B et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. 1998 Transplant. Proc. pmid:9636573
Shimizu T et al. Risk factors of acute tacrolimus nephrotoxicity in renal allografts. 2000 Transplant. Proc. pmid:11119998
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Rudich SM et al. Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. 1998 Transplant. Proc. pmid:9636574
Lauro A et al. Results of intestinal and multivisceral transplantation in adult patients: Italian experience. 2006 Jul-Aug Transplant. Proc. pmid:16908252
Burkhalter F et al. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. 2012 Transplant. Proc. pmid:23195006
Charco R et al. Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation. 2005 Transplant. Proc. pmid:16386588
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Schneeberger H et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. 1998 Transplant. Proc. pmid:9636642
Hairhara Y et al. Effect of fluconazole on blood levels of tacrolimus. 1999 Transplant. Proc. pmid:10578284
Jain A et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. 2005 Transplant. Proc. pmid:15848671
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. 1997 Transplant. Proc. pmid:9365633
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Jonas S et al. Cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up. 2002 Transplant. Proc. pmid:12176459
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Marcén R et al. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. 2006 Transplant. Proc. pmid:17097957
Borrows R et al. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results. 2005 Transplant. Proc. pmid:15919468
Gozdowska J et al. Safety and tolerance of sodium mycophenolate in patients after renal transplantation--an observational study. 2009 Transplant. Proc. pmid:19857665
Tsuchida Y et al. Vascularized bone marrow allotransplantation in rats prolongs a simultaneous skin allograft. 1997 Transplant. Proc. pmid:9142252
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Lo CM et al. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. 1998 Transplant. Proc. pmid:9838571
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Reichenspurner H et al. Tacrolimus-based immunosuppressive protocols in lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083062
Choi JY and Kwon OJ Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants? 2013 Transplant. Proc. pmid:24156999
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Tsuchida T et al. The development of humanized liver with Rag1 knockout rats. 2014 Transplant. Proc. pmid:24815157
Aumente Rubio MD et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. 2003 Transplant. Proc. pmid:12962871
Mange KC and Bloom RD Rates of acute rejection by recipient race and type of calcineurin inhibitor with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12493393
Domenech N et al. Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. 2003 Transplant. Proc. pmid:12962873
Boots JM et al. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? 2002 Transplant. Proc. pmid:12493409
Peraira JR et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. 2003 Transplant. Proc. pmid:12962875
Khanna A et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123118
Busuttil RW and Holt CD Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123119
Gurkan A et al. Comparison of tacrolimus and neoral-based immunosuppressive regimens in renal transplantation patients: singles-center experience. 2002 Transplant. Proc. pmid:12176525
Villanueva ME et al. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. 2008 Transplant. Proc. pmid:18790198
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Wayman MR et al. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. 2002 Transplant. Proc. pmid:12176526
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Limsrichamrern S et al. Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27320581
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Mor E et al. Homocysteine levels among transplant recipients: effect of immunosuppressive protocols. 2001 Transplant. Proc. pmid:11543802
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Kokado Y et al. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083515
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Matsumiya G et al. Serum interleukin-6 level after cardiac xenotransplantation in primates. 1997 Feb-Mar Transplant. Proc. pmid:9123586
Schweizer RT and Meisterling LD Tolerability of mycophenolate mofetil in organ transplant recipients. 2001 Transplant. Proc. pmid:11377540
Pham SM et al. Sirolimus and tacrolimus in clinical cardiac transplantation. 2002 Transplant. Proc. pmid:12176597
Zhou J et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. 2008 Transplant. Proc. pmid:19100435
Glanemann M et al. Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267194
van den Berg AP et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. 2001 Feb-Mar Transplant. Proc. pmid:11267197
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Filler G et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. 2004 Transplant. Proc. pmid:15251324
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Grabczewska Z et al. Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index. 2013 Transplant. Proc. pmid:23726621
Chen H et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9745497
Pankewycz O et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. 2011 Transplant. Proc. pmid:21440749
Treede H et al. Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. 2001 Feb-Mar Transplant. Proc. pmid:11267444
Fu Q et al. Risk Factors for Acute Rejection After Deceased Donor Kidney Transplantation in China. 2018 Transplant. Proc. pmid:30316380
Chen H et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9636419
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Pinho-Apezzato ML et al. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. 2010 Transplant. Proc. pmid:20620519
Filler G Optimization of immunosuppressive drug monitoring in children. 2007 Transplant. Proc. pmid:17524944
Halim MA et al. De novo Crohn's disease in a renal transplant recipient. 2007 Transplant. Proc. pmid:17524953
Guleria S et al. Tacrolimus (Pan Graf) in live related renal transplantation: an initial experience of 101 recipients in India. 2007 Transplant. Proc. pmid:17445588
Rodriguez Cubillo B et al. Risk Factors of Recurrence of Diabetic Nephropathy in Renal Transplants. 2016 Transplant. Proc. pmid:27932117
Hariharan S et al. Conversion from cyclosporine to tacrolimus after pancreas transplantation. 1995 Transplant. Proc. pmid:8539799
Hartwig T et al. Low-dose sirolimus and tacrolimus in kidney transplantation: first results of a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750383